We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively... Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. Show more
Ask ADVFN Intelligence (AI)
Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 31, 2025 NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar...
Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301...
BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar...
BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Symbol | Price | Vol. |
|---|---|---|
| TCTMTCTM Kids IT Education Inc | US$ 0.764 (321.87%) | 729.72M |
| NVDANVIDIA Corporation | US$ 120.07 (-3.67%) | 388.54M |
| RIMEAlgorhythm Holdings Inc | US$ 0.02565 (5.12%) | 338.75M |
| BHATBlue Hat Interactive Entertainment Technology | US$ 0.0355 (-11.25%) | 236.29M |
| CLEUChina Liberal Education Holdings Ltd | US$ 0.1938 (30.77%) | 234.8M |
Monksdream
6 months ago
Monksdream
6 months ago
Monksdream
6 months ago
Monksdream
7 months ago
Monksdream
7 months ago
Monksdream
8 months ago
Monksdream
8 months ago
Monksdream
9 months ago
Monksdream
9 months ago
Monksdream
9 months ago
Monksdream
10 months ago
Firestorm22
10 months ago
Monksdream
10 months ago
fink
12 months ago
Terpi
1 year ago
Monksdream
1 year ago
TheFinalCD
2 years ago
crudeoil24
3 years ago
crudeoil24
3 years ago
crudeoil24
3 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
